Pharmaceutical — Goodwill (Note 3)
Business Segments · Goodwill (Note 3)Johnson & Johnson Pharmaceutical — Goodwill (Note 3) decreased by 0.4% to $14.27B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 28.4%, from $11.11B to $14.27B. Over 2 years (FY 2021 to FY 2024), Pharmaceutical — Goodwill (Note 3) shows relatively stable performance with a -0.2% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2013
Last reportedQ3 2025
Rolls up toGoodwill
How to read this metric
An increase suggests recent acquisitions, while a decrease may indicate impairment charges or divestitures.
Detailed definition
Represents the total carrying value of goodwill attributed to the Innovative Medicine operating segment as reported in f...
Peer comparison
Commonly reported by large pharmaceutical companies as 'Goodwill' under segment assets.
Metric ID:
jnj_segment_innovative_medicine_goodwill_note_3Historical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.75B | $10.81B | $10.73B | $10.58B | $10.41B | $10.04B | $10.18B | $10.31B | $10.15B | $10.41B | $10.55B | $10.77B | $11.11B | $10.69B | $10.91B | $14.33B | $14.27B |
| QoQ Change | — | +0.5% | -0.7% | -1.4% | -1.6% | -3.6% | +1.5% | +1.2% | -1.5% | +2.5% | +1.4% | +2.0% | +3.2% | -3.8% | +2.0% | +31.3% | -0.4% |
| YoY Change | — | — | — | — | -3.1% | -7.1% | -5.1% | -1.0% | +1.1% | +2.2% | — | +4.5% | +9.5% | +2.7% | +3.4% | +33.0% | +28.4% |
Range$10.04B – $14.33B
CAGR+7.3%
Avg YoY Growth+5.7%
Median YoY Growth+2.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's pharmaceutical — goodwill (note 3)?
- Johnson & Johnson (JNJ) reported pharmaceutical — goodwill (note 3) of $14.27B in Q3 2025.
- How has Johnson & Johnson's pharmaceutical — goodwill (note 3) changed year-over-year?
- Johnson & Johnson's pharmaceutical — goodwill (note 3) increased by 28.4% year-over-year, from $11.11B to $14.27B.
- What is the long-term trend for Johnson & Johnson's pharmaceutical — goodwill (note 3)?
- Over 2 years (2021 to 2024), Johnson & Johnson's pharmaceutical — goodwill (note 3) has grown at a -0.2% compound annual growth rate (CAGR), from $43.29B to $43.12B.
- What does pharmaceutical — goodwill (note 3) mean?
- The total value of goodwill recorded for the Innovative Medicine business segment.